Endocrine Abstracts

Introduction: Sex steroid hormones play a key role in bone health, however medical therapies for gender dysphoria lead to hormonal changes.

Purpose: Understanding the change in bone mass and body composition is extremely important, because this treatment will be carried out over a long period of time

Methods: In a prospective study, we included 19 transgender men (female-to-male trans persons) before treatment and after 1 year of treatment with undecanoate (1000 mg i.m./12 weeks). Bone densitometry model Hologic-Discovery performed at baseline and after 6, 12 months of therapy. All participants signed the TCLE, project approved by CEP-CAAE: 36823220.6.0000.0062.

Results: Analysis of 19 transgender men with a mean age of 24 years +/- 10 years. LS-BMD (lumbar spine) at initial time (0 m) 1,075±0,238 g/cm² and after 6 months (6 m) 1,044±0,117 g/cm² and 12 months (12 m) after 1,052±0.122 g/cm²,P=0.21; FN-BMD (Femur Neck) 0 m= 0.904±0.121 g/cm²; 6 m= 0.918±0.108 g/cm² and 12 m= 0.905±0.107 g/cm²;P=0.90. TH-BMD (Total Hip) 0 m=1.017±0.139 g/cm²; and 6 m= 1.023±0.134 g/cm²; 12 m= 1.032±0.136 g/cm²;P=0.05. About body composition: the percentage of body fat: 0 m=38.8±6.7%, 6 m=34.5±7.1%; 12 m=34.9±9.0;P=0.09; android/gynecoid ratio: 0.93±0.16, 6 m=0.94±0.17; 12 m=0.94±0.18P=0.06, VAT mass (cm3) 431.8±262.1, 6 m= 401.8±298.6, 12 m= 455.5±322.7 and Lean/Height² (kg/m²) 0 m= 15.52±3.24 6 m= 16.15±2.19 kg/m²; 12 m= 15.86±2.22 kg/m²; P<0.01 and Appen. Lean/Height² (kg/m²) 6.92±1.74, 6 m= 7.32±1.22 and 12 m= 7.31±1.07; P<0.01

Conclusion: In 1 year of hormone therapy with testosterone, we did not observe significant differences in bone mass, but in body composition there was a gain in appendicular lean mass.